August 16, 2025

Understanding Provider Treatment Approaches for the Provision of Gender-Affirming Hormones in the Current US Political Climate.

Key Points

Providers reported they follow informed consent models for prescribing gender-affirming hormone therapy, ensuring patient-centered care.
Prescribers indicated they regularly monitor health and maintain open communication with patients, emphasizing a supportive environment.
The study details how GAHT prescribers align their practices with clinical standards, similar to those for cisgender patients.
Findings shed light on ongoing efforts to support transgender individuals' access to critical healthcare in a challenging political climate.

Abstract

Transgender people's access to gender-affirming hormone therapy (GAHT) is under attack in the United States. In 2024, we interviewed US providers about how they prescribe GAHT. In accordance with informed consent models, providers reported that they reviewed patients' medical history, social supports, and comorbidities; prescribed GAHT formulations that aligned with patients' goals; monitored health regularly; and maintained open communication with patients. The GAHT prescribers followed clinical standards to mitigate risks and maximize benefits, following similar standards of care for cisgender patients. (Am J Public Health. Published online ahead of print August 14, 2025:e1-e4. https://doi.org/10.2105/AJPH.2025.308143).

AI에게 질문

Bookmark